These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38023143)

  • 21. Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system.
    Wei C; Yin W; Hu T; Zhang J; Dan H; Wu B
    Front Pharmacol; 2023; 14():1323240. PubMed ID: 38264533
    [No Abstract]   [Full Text] [Related]  

  • 22. Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database.
    Zhao H; Li JM; Li ZR; Zhang Q; Zhong MK; Yan MM; Qiu XY
    Front Pharmacol; 2023; 14():1182113. PubMed ID: 37502210
    [No Abstract]   [Full Text] [Related]  

  • 23. Ocular adverse events associated with platins: a disproportionality analysis of pharmacovigilance data and extensive systematic review of case reports.
    Hasik PN; Thomas C; Hazarika M; Undela K
    Expert Opin Drug Saf; 2024 Aug; ():1-14. PubMed ID: 39137273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wei Q; Wu X
    Front Pharmacol; 2022; 13():986357. PubMed ID: 36408225
    [No Abstract]   [Full Text] [Related]  

  • 25. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
    Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
    Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities.
    Allenbach Y; Anquetil C; Manouchehri A; Benveniste O; Lambotte O; Lebrun-Vignes B; Spano JP; Ederhy S; Klatzmann D; Rosenzwajg M; Fautrel B; Cadranel J; Johnson DB; Moslehi JJ; Salem JE
    Autoimmun Rev; 2020 Aug; 19(8):102586. PubMed ID: 32535094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database.
    Xia S; Gong H; Wang YK; Liu L; Zhao YC; Guo L; Zhang BK; Sarangdhar M; Noguchi Y; Yan M
    Front Pharmacol; 2023; 14():1129730. PubMed ID: 37007042
    [No Abstract]   [Full Text] [Related]  

  • 29. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
    Pan Y; Wang Y; Zheng Y; Chen J; Li J
    Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.
    Wang Y; Cui C; Deng L; Wang L; Ren X
    Front Immunol; 2023; 14():1127128. PubMed ID: 37292205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports.
    Palapra H; Viswam SK; Kalaiselvan V; Undela K
    Int J Clin Pharm; 2022 Dec; 44(6):1425-1433. PubMed ID: 36224513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the United States Food and Drug Administration Adverse Event Reporting System (FAERS).
    McIntyre RS; Wong S; Kwan ATH; Rhee TG; Teopiz KM; Ho R; Cao B; Mansur RB; Rosenblat JD; Le GH
    Expert Opin Drug Saf; 2024 Jun; ():1-5. PubMed ID: 38804896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiac arrhythmias associated with anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Wang F; Xu G; Wu X
    Expert Opin Drug Saf; 2023; 22(11):1127-1132. PubMed ID: 37428255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Toxicity signals associated with secukinumab: A pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Zheng Y; Guo X; Chen C; Chi L; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Br J Clin Pharmacol; 2023 Feb; 89(2):865-873. PubMed ID: 36106653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
    Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
    Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
    Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database.
    Fu Z; Liu J; Zhang C; Hu H; Li S; Zhang Y; You R
    Front Pharmacol; 2024; 15():1383212. PubMed ID: 38948476
    [No Abstract]   [Full Text] [Related]  

  • 38. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
    Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
    Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
    Gastaldon C; Raschi E; Kane JM; Barbui C; Schoretsanitis G
    Psychother Psychosom; 2021; 90(1):41-48. PubMed ID: 32854103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis.
    Zhang Y; Fang Y; Wu J; Huang G; Bin J; Liao Y; Shi M; Liao W; Huang N
    Front Pharmacol; 2022; 13():817662. PubMed ID: 35431928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.